Abstract
Transforming Growth Factor (TGF)-β inhibitors have been in development for decades with the outmost results of being promising candidates. From the latest clinical results at the 2016 ASCO meeting converging evidences suggest that we have moved from promising to effective drug nominees.
Author supplied keywords
Cite
CITATION STYLE
APA
de Gramont, A., Faivre, S., & Raymond, E. (2017). Novel TGF-β inhibitors ready for prime time in onco-immunology. OncoImmunology, 6(1). https://doi.org/10.1080/2162402X.2016.1257453
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free